{"Q": 1, "answer": "no", "rationale": "The segment contains 'very quickly' modifying 'respond', not a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_6648", "batch_size": 200, "batch_pos": 69, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "No high-potency verb, metaphor, alert phrase, superlative, or intensifier + harm noun found.", "method": "llm_batch", "batch_id": "batch_2_18544", "batch_size": 200, "batch_pos": 53, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "No moderate verbs or scale/impact information present.", "method": "llm_batch", "batch_id": "batch_3_13608", "batch_size": 200, "batch_pos": 41, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a question.", "method": "llm_batch", "batch_id": "batch_4_19788", "batch_size": 200, "batch_pos": 39, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "Reports plans/capability ('could respond very quickly'), not explicit calming language about current safety.", "method": "llm_batch", "batch_id": "batch_5_13380", "batch_size": 200, "batch_pos": 38, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "No minimiser + scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_19684", "batch_size": 200, "batch_pos": 22, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_19844", "batch_size": 200, "batch_pos": 19, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "The segment mentions 'plans to launch a small human trial', 'tailored to the new avian influenza subtype', and 'could respond very quickly', describing trial plans, vaccine adaptation capability, and response capability.", "method": "llm_batch", "batch_id": "batch_8_12012", "batch_size": 200, "batch_pos": 171, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
